Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

77P - Hypermethylation of genes HIST1H4F, Septin9 and RASSF1 as the potential biomarker for nasopharyngeal carcinoma screening

Date

10 Sep 2022

Session

Poster session 01

Presenters

Dingsheng Wen

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

D. Wen

Author affiliations

  • Key Laboratory Of Clinical Precision Medication, GDPU - Guangdong Pharmaceutical University, 510006 - Guangzhou/CN
More

Abstract 77P

Background

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in Southeast Asia, especially in southern China. There were about 129,000 new NPC cases and 34,000 deaths worldwide in 2018 according to Global Cancer Obsercatory. Even though NPC is sensitive to radiotherapy and has a 5-year survival rate of about 70%, the prognosis is poor in advanced stage. Therefore, it is important to screen NPC in the early stage. Epstein–Barr virus (EBV) infection plays important roles in the development of NPC, and EBV immunological assay is employed as a standard diagnostics of NPC, however, it is an invasive method. DNA methylation may lead to tumor initiation and progression by dysregulation of specific genes, should be a potential biomaker for NPC screening in early stage in a non-invasive format by collecting sample using the nose swab.

Methods

48 paraffin embedded NPC and 36 chronic nasopharyngitis (CN) speciments were collected from the First Affiliated Hospital of Guangdong Pharmaceutical University, China, and EBV serum antigen were assayed for all these patients. The quantitative methylation-sensitive PCR (qMS-PCR) assays were employed to analyse the methylation of HIST1H4F, Septin9 and RASSF1, after bisulfite modification of DNA which was extracted from the paraffin embedded samples using QIAamp DNA FFPE Tissue Kit. The individual and combination methylation gene results were compared with the antibody titer of EBV serum antigen on the basis of pathology.

Results

EBV serum antigen was positive in 59% of patients with NPC. The percent of patients with hypermethylation of the genes HIST1H4F, Septin9 and RASSF1 in NPC group was 69%, 67% and 60% respectively, which were higher than patients with CN with the positive rate under 30%. Interestingly, The positive rate leapt to 90.5% (19/21) when combination of these three hypermethylated genes in patients, which was more than using EBV serum antigen with the positive rate about 63% (P=0.02).

Conclusions

The combination of the hypermethylation of the genes HIST1H4F, Septin9 and RASSF1 may provide a potential biomarker for nasopharyngeal carcinoma screening in early stage.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.